{"id":3257,"date":"2025-03-18T14:46:15","date_gmt":"2025-03-18T11:46:15","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3257"},"modified":"2025-11-03T20:25:21","modified_gmt":"2025-11-03T17:25:21","slug":"biophytis-bio101-therapy-for-sarcopenia-could-bring-hope-to-duchenne-muscular-dystrophy-patients","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/biophytis-bio101-therapy-for-sarcopenia-could-bring-hope-to-duchenne-muscular-dystrophy-patients\/","title":{"rendered":"La terapia Biophytis&#039; BIO101 para el tratamiento de la sarcopenia podr\u00eda brindar esperanza a los pacientes con distrofia muscular de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">El ensayo cl\u00ednico de fase 2 SARA-INT se public\u00f3 en el Journal of Cachexia, Sarcopenia and Muscle (JCSM), la principal revista de referencia para la investigaci\u00f3n de la sarcopenia, lo que marca un estreno mundial para Biophytis, una compa\u00f1\u00eda de biotecnolog\u00eda en etapa cl\u00ednica que se especializa en la creaci\u00f3n de tratamientos para enfermedades relacionadas con la edad.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Los atributos clave del BIO101 del SARA INT Trail incluyen:<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eficacia prometedora:<\/strong> BIO101 350 mg dos veces al d\u00eda demuestra una mejora cl\u00ednicamente significativa en la prueba de caminata de 400 metros (400MWT), criterio de valoraci\u00f3n principal del estudio.<\/li>\n\n\n\n<li><strong>Excelente seguridad:<\/strong> En todas las dosis, BIO101 muestra un muy buen perfil de seguridad sin eventos adversos graves (EA) relacionados con el producto.<\/li>\n\n\n\n<li><strong>Mayor eficacia en poblaci\u00f3n de alto riesgo:<\/strong> Efecto del tratamiento nominalmente significativo frente a placebo en la velocidad de la marcha de 400 MWT en subpoblaciones de caminantes lentos y obesidad sarcop\u00e9nica<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Acerca de BIOPHYTIS<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biophytis SA, empresa de biotecnolog\u00eda en fase cl\u00ednica, se dedica a la creaci\u00f3n de f\u00e1rmacos candidatos para enfermedades relacionadas con la edad. Su principal f\u00e1rmaco candidato, BIO101 (20-hidroxiecdisona), es una peque\u00f1a mol\u00e9cula que se est\u00e1 desarrollando para enfermedades respiratorias (COVID-19, fase 2-3 finalizada), trastornos metab\u00f3licos (obesidad, fase 2 pr\u00f3xima a iniciarse) y enfermedades musculares (sarcopenia, fase 3 pr\u00f3xima a iniciarse, y distrofia muscular de Duchenne, fase 1-2 pr\u00f3xima a iniciarse).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leer m\u00e1s<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/es\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ensayos cl\u00ednicos para la distrofia muscular de Duchenne (Lista de todas las investigaciones)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The Phase 2 clinical trial SARA-INT was published in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the primary reference journal for sarcopenia research, marking a world premiere for Biophytis, a clinical-stage biotechnology company that specializes in creating treatments for age-related diseases. Key BIO101 Attributes from the SARA INT Trail include: About BIOPHYTIS A clinical-stage [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3259,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[309,308,307,66,310],"class_list":["post-3257","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-bio101","tag-bio101-therapy","tag-biophytis","tag-duchenne-muscular-dystrophy","tag-sarcopenia"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=3257"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3257\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/3259"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=3257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=3257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=3257"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}